Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations

Chiung Tong Chen, John T A Hsu, Wen Hsing Lin, Cheng Tai Lu, Shih Chieh Yen, Tsu Hsu, Yu Ling Huang, Jen Shin Song, Chun Hwa Chen, Ling Hui Chou, Kuei Jung Yen, Ching Ping Chen, Po Chu Kuo, Chen Lung Huang, H. Eugene Liu, Yu Sheng Chao, Teng Kuang Yeh, Weir Torn Jiaang

研究成果: 雜誌貢獻文章同行評審

9 引文 斯高帕斯(Scopus)

摘要

Abstract Numerous FLT3 inhibitors have been explored as a viable therapy for the treatment of acute myeloid leukemia (AML). However, clinical data have been underwhelming due to incomplete inhibition of FLT3 or the emergence of resistant mutations treated with these older agents. We previously developed a series of 3-phenyl-1H-5-pyrazolylamine derivatives as highly potent and selective FLT3 inhibitors with good in vivo efficacy using an intravenous (IV) route. However, the poor bioavailability of these pyrazole compounds limits the development of these promising antileukemic compounds for clinical use. Herein, we describe a novel class of 5-phenyl-thiazol-2-ylamine compounds that are multi-targeted FLT3 inhibitors. From this class of compounds, compound 7h was very potent against AML cell lines and exhibited excellent oral efficacy in AML xenograft models. In addition, further studies demonstrated that compound 7h exhibited potent in vitro and in vivo activities against clinically relevant AC220 (3)-resistant kinase domain mutants of FLT3-ITD.

原文英語
文章編號7887
頁(從 - 到)151-161
頁數11
期刊European Journal of Medicinal Chemistry
100
DOIs
出版狀態已發佈 - 6月 14 2015

ASJC Scopus subject areas

  • 藥物發現
  • 有機化學
  • 藥理
  • 醫藥 (全部)

指紋

深入研究「Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations」主題。共同形成了獨特的指紋。

引用此